Form 8-K - Current report:
SEC Accession No. 0000950170-23-073016
Filing Date
2023-12-26
Accepted
2023-12-26 16:01:08
Documents
13
Period of Report
2023-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alxo-20231222.htm   iXBRL 8-K 49250
2 EX-10.1 alxo-ex10_1.htm EX-10.1 89878
  Complete submission text file 0000950170-23-073016.txt   270226

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alxo-20231222_pre.xml EX-101.PRE 11011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alxo-20231222_lab.xml EX-101.LAB 15202
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alxo-20231222.xsd EX-101.SCH 2473
7 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20231222_htm.xml XML 4537
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 231513314
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)